ArticleCell reports2026
Combining genotoxic gut bacterial strains increases tumor burden and accelerates onset in a germ-free mouse model of colon carcinogenesis.
Abstract read
In one paragraph
Article in Cell reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Tamar PlittMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Alix PiessevauxMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Faculty of Medicine, Catholic University of Leuven, 3000 Leuven, Belgium.
Urvija RajpalMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Jeremy FischerMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Matthew P SpindlerMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Brigham and Women's Hospital, Division of General Internal Medicine, Boston, MA 02115, USA.
Constantin RuprechtMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Zhihua LiMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Ilaria MognoMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Ye YangDepartment of Medicine, University of Florida College of Medicine, Gainesville, FL 32610, USA.
A Nicole DeschOncology Therapeutic Area, Johnson & Johnson Innovative Medicine, Spring House, PA 19002, USA.
Gerald ChuOncology Therapeutic Area, Johnson & Johnson Innovative Medicine, Spring House, PA 19002, USA.
Zhengyu JiangOncology Therapeutic Area, Johnson & Johnson Innovative Medicine, Spring House, PA 19002, USA.
Jianyao WangOncology Therapeutic Area, Johnson & Johnson Innovative Medicine, Spring House, PA 19002, USA.
Dirk GeversOncology Therapeutic Area, Johnson & Johnson Innovative Medicine, Spring House, PA 19002, USA.
David PocalykoOncology Therapeutic Area, Johnson & Johnson Innovative Medicine, Spring House, PA 19002, USA.
Abby L GeisDepartment of Medicine, Division of Infectious Disease, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Christian JobinDepartment of Medicine, University of Florida College of Medicine, Gainesville, FL 32610, USA.
Kurtis E BachmanOncology Therapeutic Area, Johnson & Johnson Innovative Medicine, Spring House, PA 19002, USA.
Cynthia L SearsDepartment of Medicine, Division of Infectious Disease, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Graham J BrittonMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Lani R San MateoOncology Therapeutic Area, Johnson & Johnson Innovative Medicine, Spring House, PA 19002, USA.
Jeremiah J FaithMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. Electronic address: jeremiah.faith@mssm.edu.
Funding
Conduits: Mount Sinai Health System Translational Science HubUL1TR004419 · NCATS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Rosalind J Wright · 2022 to 2026
$46.4MThe Influence Of Gut Microbiota Stability In Inflammatory Bowel DiseaseR01DK112978 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Jeremiah James Faith · 2019 to 2026
$5.3MUncovering the rules of gut microbiome strain transmissionR01DK124133 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Jeremiah James Faith · 2020 to 2026
$4.2MManufacture of defined live microbial therapeutics for infectious and inflammatory diseaseR01DK141891 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Jeremiah James Faith · 2025 to 2026
$1.3MNCATS NIH HHS UL1 TR004419NIDDK NIH HHS R01 DK112978NIDDK NIH HHS R01 DK124133NIDDK NIH HHS R01 DK141891
Abstract
To identify causal links between gut microbes and tumorigenesis, we colonized germ-free, colon tumor-susceptible mice (Apc
Indexed as
CarcinogenesisColonic NeoplasmsGastrointestinal MicrobiomeAnimalsCell ProliferationDisease Models, AnimalDNA DamageGerm-Free LifeHumansMaleMiceMice, Inbred C57BLTumor Burdencolibactincolorectal cancerCP: cancerCP: microbiologyDNA damagegenotoxicitygnotobiotic micegut microbiotamicrobiomepks(+)Escherichia colireactive oxygen speciestumorigenesis
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.